Back to Search
Start Over
Prostate high dose-rate brachytherapy as monotherapy for low and intermediate-risk prostate cancer: Efficacy results from a randomized phase II clinical trial of one fraction of 19 Gy or two fractions of 13.5 Gy: A 9-year update.
- Source :
-
Radiotherapy & Oncology . Sep2024, Vol. 198, pN.PAG-N.PAG. 1p. - Publication Year :
- 2024
-
Abstract
- • Long-term outcomes of HDR brachytherapy for low and intermediate prostate cancer. • Treatment given as single 19 Gy fraction or two 13.5 Gy fractions, with 9-year follow-up. • We observed that two fractions of 13.5 Gy led to a robust, long-term PSA response with acceptable toxicity. • In contrast, a single fraction of 19 Gy yielded poor oncologic outcomes and is not recommended. • Contributes to the ongoing debate on optimal HDR monotherapy strategies to manage low and intermediate-risk prostate cancer. High dose-rate (HDR) brachytherapy as a monotherapy is an accepted treatment for localized prostate cancer, but the optimal dose and fractionation schedule remain unknown. We report on the efficacy of a randomized Phase II trial comparing HDR monotherapy delivered as 27 Gy in 2 fractions vs. 19 Gy in 1 fraction with a median follow-up of 9 years. Enrolled patients had low or intermediate-risk disease, <60 cc prostate volume and no androgen deprivation use. Patients were randomized to 27 Gy in 2 fractions delivered one week apart vs a single fraction of 19 Gy. 170 patients were randomized: median age 65 years, median follow-up 107 months and median baseline PSA 6.35 ng/ml. NCCN risk categories comprised low (19 %), favourable (51 %), and unfavourable intermediate risk (30 %). The median PSA at 8 years was 0.08 ng/ml in the 2-fraction arm vs. 0.89 ng/ml in the single-fraction arm. The cumulative incidence of local failure at 8 years was 11.2 % in the 2-fraction arm vs. 35.9 % in the single-fraction arm (p < 0.001). The incidence of distant failure at 8 years was 3.8 % in the 2-fraction arm and 2.5 % in the single-fraction arm (p = 0.6). HDR monotherapy delivered in two fractions of 13.5 Gy demonstrated a persistent cancer control rate at 8 years and was well-tolerated. Single-fraction monotherapy yielded poor oncologic control and is not recommended. These findings contribute to the ongoing discourse on optimal HDR monotherapy strategies for low and intermediate-risk prostate cancer. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 01678140
- Volume :
- 198
- Database :
- Academic Search Index
- Journal :
- Radiotherapy & Oncology
- Publication Type :
- Academic Journal
- Accession number :
- 178832441
- Full Text :
- https://doi.org/10.1016/j.radonc.2024.110381